Neurobehavioral Disorders
Novel Combination Therapy for Major Depressive Disorder Gets Priority Review
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Your search for major depressive disorder returned 5 results
Neurobehavioral Disorders
Spravato Approved for MDD With Acute Suicidal Ideation or Behavior
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Alzheimer's Disease and Dementia
Breakthrough Therapy Designation Granted to Novel Therapy for Alzheimer Disease Agitation
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease agitation.
Neurobehavioral Disorders
Prescription Digital Therapeutic for Anxiety, Depression Treatment Launched
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
Neuromuscular Disorders
Zolgensma Benefits Observed in Presymptomatic SMA Patients
The phase 3 SPR1NT trial is an ongoing open-label, single-arm study evaluating onasemnogene in presymptomatic patients (≤6 weeks of age) with a genetic diagnosis of SMA and 2 or 3 copies of survival motor neuron 2 gene.
- Loading...
Loading...
Next post in Neuromuscular Disorders
Loading... 
Loading...